Best Resources for Understanding Ketamine-Assisted Therapy

KETAMINE-ASSISTED THERAPY • March 24, 2026

The Parking Lot at 10:40 PM

It’s 10:40 on a Tuesday night, and Maha is sitting in her car in the parking lot outside a clinic she has not yet walked into. She’s 44, a pharmaceutical regulatory affairs director, the person her whole department calls when a submission is about to go sideways. She has three browser tabs open on her phone. One is the clinic’s intake form, half filled out. One is a PubMed abstract she’s read four times. One is a Reddit thread she probably shouldn’t be reading at this hour. The overhead light in the clinic’s waiting room is still on. She isn’t ready to go in. She isn’t ready to leave, either.

“I’ve done everything they told me to do,” she said, the first time we met, two weeks earlier. “Three SSRIs. An SNRI. Eighteen months of CBT. A course of EMDR that helped some things and not this. My psychiatrist finally said the words treatment-resistant, and I went home and researched what that actually meant for six hours straight, because apparently that’s who I am, I research things at 1 a.m. instead of sleeping.” She laughed, but it wasn’t really a laugh. “Now I’m looking at ketamine and I don’t know if I’m looking at medicine or if I’m looking at something I want to be medicine because I’m exhausted.”

Sitting with Maha that evening, I felt the particular tension I’ve come to recognize in driven women who arrive at this specific fork in the road. Not desperation, exactly. Something more controlled than that. A woman who has spent years running her own recovery like a project, gathering data, cross-checking sources, refusing to let hope get ahead of evidence, and who has finally hit a treatment option serious enough that the data itself feels frightening to read closely.

What I’ve come to think of as the parking lot moment is this exact pause. It isn’t indecision. It’s a driven woman doing the one thing she knows how to do, which is due diligence, applied to a question no spreadsheet can fully answer: whether to trust a treatment that is real, promising, and still genuinely limited, with her own mind. (Maha and Nona, who you’ll meet shortly, are composites, and identifying details have been changed to protect client confidentiality.)

I want to say clearly, before we go any further: I’m a licensed trauma therapist. I don’t prescribe ketamine, and I don’t administer it. What I can offer is what fifteen-plus years of clinical hours with driven women have taught me about how to think clearly about a treatment like this, what the research actually supports, where it stops supporting anything, and how to find the kind of medically supervised care that takes both the medicine and the therapy seriously. This is educational information, not medical advice. Any decision about ketamine belongs in conversation with a qualified psychiatrist or physician who can evaluate your full history.

What Is Ketamine-Assisted Therapy, Actually?

Ketamine has an odd biography for a psychiatric treatment. It was developed in the 1960s as a surgical anesthetic, and it’s still used that way in emergency rooms and operating rooms today. Somewhere along the way, researchers noticed that at much lower, sub-anesthetic doses, it did something unexpected to mood. It didn’t just sedate. It seemed to loosen depression’s grip, sometimes within hours, in people for whom nothing else had worked.

That distinction, the psychotherapy wrapped around the ketamine sessions rather than the ketamine dose alone, is the whole reason the field distinguishes KAP from a ketamine infusion. You can receive IV ketamine at a medical infusion clinic with monitoring and nothing else. You can receive esketamine, the FDA-approved nasal spray formulation, through a psychiatrist’s office as part of a structured protocol. Or you can do ketamine-assisted psychotherapy, where a licensed psychotherapist works with you on preparation before the session, presence or integration support during and after it, and ongoing talk therapy to metabolize what came up. These are related but genuinely different models of care, and the research doesn’t support treating them as interchangeable.

The proposed mechanism is where it gets genuinely interesting, and where I want to be careful not to overstate what’s settled science. Ketamine acts on NMDA glutamate receptors in the brain, which is a very different pharmacological pathway than SSRIs use. Researchers believe this rapid glutamate action may trigger a burst of synaptic growth, essentially prompting the brain to build new connections faster than it does through the slower monoamine pathways SSRIs work through. That’s the leading hypothesis. It isn’t fully proven, and neuroscientists are still refining exactly how it produces the antidepressant effect some patients experience within hours rather than the weeks typical SSRIs require.

What this means in practice, for a woman like Maha sitting in that parking lot, is that ketamine isn’t simply “a faster antidepressant.” It’s a different category of intervention, one that appears to create a window of neuroplasticity, a period where the brain may be unusually receptive to new patterns. Whether that window gets used well depends heavily on what happens inside it: what a person processes, with whom, and whether the insight gets integrated into daily life afterward. That’s the therapy part. Without it, you’re left holding an open window and nothing to do with the air.

What Does the Research Actually Show?

Here’s what I think the research supports, stated as plainly as I can, and here’s where I think it stops.

Gerard Sanacora, MD, PhD, a Yale psychiatrist and one of the senior investigators on the most rigorous head-to-head ketamine trial published to date, co-authored a 2023 New England Journal of Medicine study comparing ketamine directly against electroconvulsive therapy (ECT) for nonpsychotic treatment-resistant depression. The trial found ketamine performed comparably to ECT, long considered the most effective treatment for severe, treatment-resistant depression, in this patient population (PMID 37224232). I’ve sat with that finding for a while, because it’s a genuinely significant result. It says ketamine isn’t a fringe alternative therapy being oversold to desperate people. In a well-designed trial, it held up against the treatment psychiatry has trusted most for decades.

Adriana Feder, MD, a psychiatrist at Mount Sinai who has spent years studying ketamine specifically for trauma-related conditions, led a randomized controlled trial published in 2021 in the American Journal of Psychiatry examining repeated ketamine administration for chronic PTSD. Her team found that repeated infusions produced meaningfully greater symptom reduction than a control condition (PMID 33397139). This one matters to me clinically because so much of what I see in driven women isn’t depression in isolation. It’s depression braided through years of unresolved trauma, and a treatment that shows promise for both conditions is worth taking seriously.

Then there’s esketamine, the intranasal formulation the FDA approved specifically for treatment-resistant depression. Konstantinos Fountoulakis and colleagues published a 2025 systematic review and meta-analysis in the American Journal of Psychiatry pooling the esketamine trial data, and the picture that emerged was one of real but modest average effects, with meaningful variation in who responds and by how much (PMID 39876682). Not everyone improves. Some people improve substantially. The average effect sits somewhere in between, which is a very different story than “breakthrough cure,” and it’s the story I think driven women deserve to hear before they invest money and hope into a protocol.

Now here’s the part I don’t think gets said enough, and it’s the part I most want you to sit with if you’re where Maha was in that parking lot. Sanne Smith-Apeldoorn and colleagues published a systematic review in Lancet Psychiatry in 2022 specifically examining maintenance ketamine treatment, meaning what happens when people keep receiving ketamine over months or years to sustain an initial response. Their review found that the evidence base for long-term maintenance dosing is thin, that durability of benefit after an initial course is genuinely uncertain for many patients, and that safety and tolerability data over extended use periods remain limited (PMID 36244360). In my own read of the field, this is the honest asterisk that belongs on every conversation about ketamine’s promise. The acute response, especially paired with therapy, can be real and can be significant. What happens six months or two years later, whether people need ongoing sessions indefinitely, what the cumulative risks of repeated dosing actually are, is still being worked out by researchers, not settled.

I want to name the other limits honestly too, because a therapist who only tells you the good news isn’t being a good clinician. Ketamine carries real abuse potential; it’s a controlled substance for a reason, and dissociative experiences that feel meaningful in a supervised clinical setting can become something else entirely outside one. It’s genuinely expensive in the United States, often costing thousands of dollars across a treatment course, and insurance coverage remains inconsistent, which means access tracks income in a way that should trouble anyone paying attention. And it isn’t a standalone fix. Every clinician and researcher I trust in this space, including the ones cited above, frames ketamine as most effective when paired with skilled psychotherapy, not as a replacement for the work of therapy itself. A person who receives ketamine without any therapeutic support is doing something closer to a medical procedure than to psychiatric treatment in the fuller sense.

How Does This Show Up in Driven Women’s Lives?

What I see in practice, across years of sitting with driven women who arrive at the ketamine question, is a pattern specific enough that I now expect it in the intake conversation. She has typically tried the first-line treatments conscientiously and completely. She has typically kept working through all of it, because stopping was never really presented to her as an option. And she typically frames the decision to explore KAP not as desperation but as the next rigorous, well-researched step, which is both true and, I think, worth examining gently.

Six weeks after that first parking lot conversation, Maha came back to session having done what she does. She’d read the New England Journal of Medicine trial in full, not just the abstract. She’d called two KAP practices and asked both about their integration protocols before asking about pricing. “I noticed something,” she told me, turning her water bottle slowly on the table between us. “I was doing the same thing with this research that I do at work when a submission is in trouble. I was trying to control the outcome by controlling the information. And I don’t think that’s wrong, exactly. But I think it might be the thing keeping me in the parking lot instead of walking in.”

Not always, but often enough that I now name it directly with clients considering KAP: the same over-functioning, research-first orientation that built a driven woman’s career can become, at this particular juncture, a way of postponing a decision that ultimately can’t be fully de-risked by more reading. That isn’t a criticism of due diligence. Due diligence here is exactly right. It’s an observation about the point at which due diligence has done what it can do, and something else, trust in a vetted process and a good clinical team, has to take over.

This is also, frequently, where I see driven women confront a harder truth than the pharmacology: that treatment-resistant depression or chronic trauma symptoms are not a personal failing, and that needing something beyond talk therapy and medication isn’t evidence you did the earlier work wrong. You’re not broken because SSRIs didn’t fully resolve this. You’re not failing because eighteen months of good CBT helped some things and not others. Some depression and some trauma genuinely require different tools, and looking for the next one is not a referendum on the tools you already tried.

The Resources That Actually Help

These are the resources I actually point clients toward when they’re at the research stage Maha was in. None of them replace an evaluation with a qualified psychiatrist. All of them make that evaluation more useful, because you’ll arrive with better questions.

Beyond books, the single most useful thing I ask clients to do is look for a KAP program specifically, not a generic ketamine infusion clinic. The difference matters more than the marketing usually reveals. Nona, a UX researcher in her late thirties, learned this distinction the harder way. She’d found a clinic through an Instagram ad that promised “rapid relief” and offered same-day appointments with no intake questionnaire beyond a basic health screen. “They didn’t ask about my trauma history at all,” she told me. “They didn’t ask if I had support at home afterward. They took a card number and told me to arrive with an empty stomach.” She left after the consultation, uneasy, and found a second practice instead, one where the intake process took ninety minutes, included a psychiatric evaluation, and explicitly required a minimum number of integration therapy sessions as part of the protocol. “The second place made me wait three weeks longer,” she said. “I was almost annoyed about that. Now I think the waiting was the point.”

What separates a legitimate, medically supervised KAP program from the kind of clinic Nona initially found usually comes down to a few concrete markers: a thorough psychiatric intake that screens for contraindications like uncontrolled hypertension, psychosis history, or active substance use disorder; medical staff present and monitoring vitals during dosing; a licensed psychotherapist involved in preparation and integration, not just a medical provider administering the drug; and a clear plan for what happens between sessions, not just during them. If a clinic can’t describe its integration therapy model in specific terms, that’s information.

The American Psychiatric Association and the American Society of Ketamine Physicians, Psychotherapists and Practitioners both maintain provider directories that filter for clinics following consensus safety guidelines, and I point clients there before Google. Psychology Today’s therapist finder also lets you filter specifically for clinicians trained in ketamine-assisted psychotherapy, which is a useful way to locate the therapy half of the model, not just the medical half.

What Questions Should You Ask a Provider?

I keep a short list of questions I encourage clients to bring into a KAP consultation, because the answers reveal more than any brochure will.

Ask what the full protocol looks like, start to finish, not just the dosing sessions. A legitimate program should be able to describe preparation sessions, dosing sessions, and integration sessions as three distinct phases with distinct goals. Ask who is medically present during dosing and what their credentials are. Ask what happens if you have a difficult psychological reaction during a session, not just a medical one. Ask how they screen for contraindications, and specifically ask whether they’ve reviewed your full psychiatric and medical history, not just handed you a form. Ask what the total cost is across a full course, including integration therapy, because the sticker price on the ketamine sessions alone is rarely the real number. And ask, directly, what they believe the evidence does and doesn’t support for someone with your specific history. A provider who answers that last question with a hedge and a nuanced, honest answer is one I’d trust more than a provider who answers with total certainty.

This is also where I think it’s worth saying plainly: this whole area of medicine moves quickly, and a program’s protocols today may look different from a program’s protocols eighteen months from now as the maintenance-dosing evidence discussed earlier continues to develop. A good provider stays current with that shifting evidence base and will tell you when guidance has changed. That’s a better sign than confidence.

Both/And: Can the Medicine and the Meaning Both Be True?

I think the most useful frame I can offer here is a both/and, because the either/or versions of this conversation, the breathless psychedelic-renaissance hype on one side and the dismissive “it’s just a dissociative drug” skepticism on the other, both miss what’s actually happening in the room with a client.

Ketamine can produce a real, measurable, sometimes rapid shift in mood and trauma symptoms, documented across serious trials discussed earlier in this guide. AND that shift, on its own, doesn’t constitute healing. The window opens. What a person does inside the window, the meaning they construct from a dissociative experience, the trauma material that surfaces and needs a skilled therapist to help metabolize it, the daily-life changes that have to follow if the improvement is going to hold, is where the actual work lives. The medicine creates possibility. It doesn’t do the possibility’s work for you.

I watched Maha find her own version of this both/and, a few months into her process, after she’d completed an intake with a program that required six integration sessions alongside three dosing sessions. “I keep waiting for it to feel like the SSRIs,” she said. “Like a switch. It doesn’t feel like a switch. It feels like something got quieter, and now I have to actually do something with the quiet, and that part is still just therapy. Slow, ordinary therapy.” She wasn’t disappointed when she said it. She sounded, for the first time in our work together, a little relieved. The medicine hadn’t done the work for her. It had made the work possible to do.

Holding both of these truths at once, that ketamine is a legitimate and sometimes significant clinical tool, and that it isn’t a substitute for the slower relational and somatic work of therapy, is exactly the kind of nuanced thinking driven women are good at everywhere else in their lives. It’s only in the world of their own mental health that the pressure to find one clean answer tends to override that capacity.

The Systemic Lens: Who Actually Gets Access to This Care?

It’s worth naming the structural layer here, because individual due diligence, however careful, operates inside a system that isn’t neutral. Ketamine-assisted psychotherapy is expensive, often several thousand dollars across a full course, and insurance coverage remains patchy and inconsistent depending on formulation, diagnosis, and state. Esketamine has a more established path to insurance coverage than off-label IV ketamine or boutique KAP programs, which means the treatment most tied to psychotherapy integration is frequently the treatment least likely to be covered.

That cost structure quietly filters who gets to access this care. A driven, well-compensated professional like Maha can weigh a five-thousand-dollar course of treatment against years of diminished functioning and decide it’s worth the investment. A woman earning less, carrying the same treatment-resistant depression, often can’t make that same calculation, regardless of how well the treatment might work for her. This isn’t a flaw in the research. It’s a flaw in how access to serious mental health innovation gets distributed in the United States, where insurance architecture and out-of-pocket cost function as a gatekeeping system independent of clinical need.

There’s a second systemic thread worth naming honestly, which is the broader commercialization of psychedelic-adjacent medicine over the past several years. Venture-funded ketamine startups have moved quickly, sometimes faster than the clinical infrastructure and integration training could keep pace with, and marketing language in this space frequently outruns what the esketamine meta-analysis discussed earlier actually found, a real but modest average effect, not a universal breakthrough. I think driven women, who are often targeted precisely because they research thoroughly and can pay out of pocket, deserve better than hype dressed up as science. You’re allowed to want this treatment to work and still read the marketing with real skepticism.

There’s also a subtler pressure worth naming, one I see specifically in ambitious, high-functioning clients: the expectation that they should be able to optimize their way out of depression the way they’ve optimized everything else in their lives, and that a fast-acting treatment like ketamine fits that expectation more comfortably than the slower work of ordinary therapy does. That expectation isn’t a personal failing either. It’s the water driven women swim in professionally, applied, understandably, to their own suffering. Naming it doesn’t mean KAP is the wrong choice. It means the choice deserves to be made without that particular pressure doing the deciding.

What Does a Path Forward Actually Look Like?

If you’re where Maha was in that parking lot, here’s what I’d actually suggest, in order. Start with your own psychiatrist or a psychiatric consultation, not a KAP clinic’s marketing page, and ask directly whether you’re a reasonable candidate given your full medical and psychiatric history. Bring the questions from earlier in this guide into that conversation. Read at least one source written by clinicians actually practicing this work, not just a testimonial page. If you move forward, choose a program that treats the psychotherapy as load-bearing, not decorative, and expect the intake process to take real time, because that’s a feature, not a delay.

And hold, as you go, the both/and we named earlier: this can be a legitimate, evidence-supported option worth exploring seriously, and it isn’t a shortcut around the work, and both of those things can be true on the same Tuesday night in the same parking lot.

Maha did eventually walk into that clinic, five weeks after the night she sat outside it. Not because the research had resolved every uncertainty; it hadn’t, and I’d told her honestly that some of it wouldn’t. She walked in because she’d found a program with a psychiatrist who answered her hardest questions with specifics instead of certainty, and a therapist who would be in the room with her afterward, not just a nurse checking her vitals and sending her home. The water bottle wasn’t on the table between us anymore, the last time we talked about it. She still doesn’t know, six months in, exactly how much of what’s shifted is the ketamine and how much is the two of us doing slower work in the sessions around it. She’s stopped needing that question fully answered before she trusts what’s changing.

Frequently Asked Questions

Warmly, Annie

Medical Disclaimer